Hola,
¿eres nuevo aquí?

Regístrate gratis y conecta tu empresa con financiación pública, partners y proyectos.

Tengo cuenta

Regístrate

Ver video

AngioResist

Financiado

Cerrado

Coordinated Development of Inhibitors and Biomarkers for Resistance to Antiangio...

Coordinated Development of Inhibitors and Biomarkers for Resistance to Antiangiogenics in Cancer AngioResist Many anti-angiogenic drugs are clinically used in several types of cancer to block angiogenesis, impair tumor growth, progression and dissemination. Nevertheless, clinical trials report emergence of resistance to treatment and a f... ver más

28/02/2018

INSTITUT CATALA D'...

150K€

Presupuesto del proyecto: 150K€

Líder del proyecto

INSTITUT CATALA D'ONCOLOGIA Actividades hospitalarias organismos publicos

TRL 4-5 | 260K€

Fecha límite participación Sin fecha límite de participación.

Ver 2 Participantes

Financiación concedida El organismo H2020 notifico la concesión del proyecto el día 2018-02-28

ERC-PoC-2015: ERC Proof of Concept Grant

I+D

Cerrada hace 10 años

0% 100%

Información adicional privada

No hay información privada compartida para este proyecto. Habla con el coordinador.

2 Participantes

INSTITUT CATALA D'ONCOLOGIA

149.93K€ | Lider

ARTICULOS FERRETERIA

Proyectos interesantes

SAF2015-70820-ERC

Medical Technol...

Data Science

60K€ Cerrado

SAF2010-15661

Medical Technol...

Data Science

145K€ Cerrado

ALTANGIOTARGET

Medical Technol...

Data Science

162K€ Cerrado

TACT

Medical Technol...

Data Science

3M€ Cerrado

ANGIO-IMAGE

Medical Technol...

Data Science

71K€ Cerrado

HOSTRESPONSE

Medical Technol...

Data Science

1M€ Cerrado

Conecta tu I+D

¿Tienes un proyecto y buscas un partner? Gracias a nuestro motor inteligente podemos recomendarte los mejores socios y ponerte en contacto con ellos. Te lo explicamos en este video

Duración del proyecto: 18 meses Fecha Inicio: 2016-08-04
Fecha Fin: 2018-02-28

Líder del proyecto

INSTITUT CATALA D'ONCOLOGIA Actividades hospitalarias organismos publicos

TRL 4-5 | 260K€

Presupuesto del proyecto 150K€

Fecha límite de participación Sin fecha límite de participación.

Descripción del proyecto Many anti-angiogenic drugs are clinically used in several types of cancer to block angiogenesis, impair tumor growth, progression and dissemination. Nevertheless, clinical trials report emergence of resistance to treatment and a failure in long-lasting effects of these therapies. To date, resistant patients do not currently have any established, proven alternative therapeutic possibility and the medical field is moving towards a careful selection of subgroups or subtypes of patients that have to be treated with each one of the available second-line targeted drugs. For this relevant unmet medical need, many laboratories and pharmaceutical companies have focused on developing new biomarkers and new drugs to fight anti-angiogenic resistance, but up to date, there is no proven established biomarker or method to predict which patient’s tumor is resistant to antiangiogenic therapies and which drug is capable of blocking this resistance to therapy. AngioResist PoC aims at solving the existing patient selection gap in the treatment of cancer that is therapeutically resistant to antiangiogenic drugs. Based on data generated from our ERC project and two filed European Patent applications, AngioResist PoC will transform the acquired basic knowledge into an Innovation project, to validate a novel biomarker of response/resistance to antiangiogenics together with a new inhibitor for the treatment of these selected patients. The project will coordinately perform the preclinical phases of development of the drug compound and the biomarker, with the final aim of licensing them both to a selected partner during the clinical phases. Together with our licensee, we aim at the final distribution of a therapeutic drug that will be delivered with a biomarker kit for the selection and treatment of cancer patients resistant to antiangiogenic drugs.

Conecta tu I+D

Entra hoy

¿Olvidé mi contraseña?

Financiación

Empresas

CTIs/Universidades

Proyectos

Investigadores